Stability and Experience
Dotarem® (gadoterate meglumine) injection, the first macrocyclic and ionic gadolinium-based contrast agent (GBCA) on the market1
Due to its chemical structure, Dotarem® offers high thermodynamic and kinetic stability to minimize the risk of free gadolinium (Gd3+) released. 7,8
Dotarem® by Guerbet has been trusted for clinical use by radiologists for over 30 years** and is known for high molecular stability.7 With more than 140 million global doses administered,12 Dotarem delivers an effective contrast-enhanced MR examination with dependable consistency.2
Dotarem presentation sizes were developed to best fulfill the needs of our radiologists.
Driven by its commitment to advance radiology, Guerbet Diagnostic Imaging has designed a comprehensive and complete portfolio of products and solutions for diagnostic imaging.
Diagnostic Imaging Solutions for RadiologyReferences
GU03230032
WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS (NSF) Risk Associated with Intrathecal Use Nephrogenic Systemic Fibrosis The risk for NSF appears highest among patients with: o Chronic, severe kidney disease (GFR < 30 mL/min/1.73m2), or o Acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. |
Indications and Usage
DOTAREM® (gadoterate meglumine) injection is a prescription gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.
Contraindications
History of clinically important hypersensitivity reactions to DOTAREM.
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see the full Prescribing Information, including the Medication Guide, for additional important safety information.